Convergence Investment Partners LLC Purchases 10,712 Shares of Bristol Myers Squibb Company $BMY

Convergence Investment Partners LLC lifted its position in Bristol Myers Squibb Company (NYSE:BMY) by 10.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 112,072 shares of the biopharmaceutical company’s stock after buying an additional 10,712 shares during the quarter. Bristol Myers Squibb comprises 1.2% of Convergence Investment Partners LLC’s investment portfolio, making the stock its 14th largest holding. Convergence Investment Partners LLC’s holdings in Bristol Myers Squibb were worth $6,045,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in BMY. Brighton Jones LLC grew its stake in shares of Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC grew its stake in shares of Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 2,786 shares in the last quarter. United Bank grew its stake in shares of Bristol Myers Squibb by 15.0% in the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after buying an additional 3,277 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $221,000. Finally, Nebula Research & Development LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $405,000. Institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.05% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on BMY shares. HSBC boosted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Bank of America reduced their target price on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, April 9th. Wells Fargo & Company restated an “outperform” rating and issued a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Guggenheim restated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Finally, Barclays started coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 target price for the company. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $61.31.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb’s $15.2 billion collaboration and licensing deal with Hengrui Pharma expands its pipeline with 13 early-stage programs, a major long-term growth catalyst. Bristol-Myers Strikes $15.2 Billion China Drug Deal
• Positive Sentiment: Zacks Research raised earnings estimates for FY2026, FY2027, FY2028 and several quarterly periods, suggesting improved profitability expectations for BMY. MarketBeat Bristol Myers Squibb estimates update
• Positive Sentiment: Tempus expanded its strategic collaboration with Bristol Myers Squibb to use AI and real-world data to improve clinical development success in oncology and neuroscience. Tempus expands strategic collaboration with Bristol Myers Squibb
• Positive Sentiment: Tigerlily Foundation announced a collaboration with Bristol Myers Squibb to expand clinical trial access and reduce participation barriers, supporting the company’s ESG and patient-access profile. Tigerlily Foundation collaborates with Bristol Myers Squibb
• Neutral Sentiment: Bristol Myers Squibb presented at the Bank of America Global Healthcare Conference, which is typically informational rather than a direct stock-moving event. Bristol-Myers Squibb Company presents at conference transcript
• Neutral Sentiment: Analyst commentary on BMY’s valuation and “buy, sell, or hold” status adds context, but it does not appear to be a new fundamental catalyst. Bristol-Myers Squibb buy sell or hold post Q1 earnings
• Negative Sentiment: One article highlighted a recent pullback in BMY shares, reminding investors that momentum has been uneven despite the recent rally. Bristol-Myers Squibb Stock Falls 3.9% After May 2026 Pullback

Bristol Myers Squibb Stock Up 0.5%

BMY opened at $57.04 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The firm has a market cap of $116.48 billion, a P/E ratio of 16.02, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26. The business has a 50 day moving average price of $58.63 and a 200 day moving average price of $55.35. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same period in the previous year, the company earned $1.80 earnings per share. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.31 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were issued a dividend of $0.63 per share. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. Bristol Myers Squibb’s payout ratio is 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.